Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
11 evidence topics · 34 sources
Summary: undertreatment, route of administration, persistence, and access
- Undertreatment: from 2003 through 2011, 23.6% to 35.5% of people with moderate psoriasis and 9.4% to 29.7% with severe psoriasis were untreated, 52.3% of those with psoriasis were dissatisfied with their treatment, and among those treated, 29.5% with moderate and 21.5% with severe psoriasis received topical agents alone. Of an estimated 1.7 million insured U.S. patients with moderate to severe psoriasis, 1 million (59%) were not treated in the preceding year, 807,000 had lapsed treatment, and 547,000 were treatment-naive; 40.9% were receiving therapy in the 12 months up to September 2012, and 22.5% of those treated received a biologic. In another study, more than 80% of psoriasis patients with ≥ 4 palms body surface area received no treatment or topical treatment only, and 45% had not seen a physician in a year.
- Route of administration: respondents in one preference study were willing to accept a reduction from approximately 70% to 40% in the proportion achieving clear or almost-clear skin to avoid injections at home and use a topical treatment. In a survey of 178 patient and 43 dermatologist respondents, both groups preferred oral to injectable treatments for moderate disease when attributes were held equal, and patients with higher needle fear were more likely to favor an oral treatment. Biologics are available only by injection or infusion. In the joint AAD-NPF phototherapy guideline, narrowband UVB is recommended 3 times weekly in the treatment phase, and travel to a phototherapy center can be a limiting factor.
- Persistence and switching: a meta-analysis of fifty-five studies estimated the proportions adherent and persistent to biological therapy at 0.61 (95% CI 0.48–0.73) and 0.63 (0.57–0.68), highest for ustekinumab and lowest for etanercept. Among 7997 biologic-treated people, switch rates were 14.4% at 12 months and 26.0% at 24 months; IL-23 inhibitors had the lowest risk of switching, with 8.5% for risankizumab and 15.7% for guselkumab over 24 months. The British Association of Dermatologists decision aid, drawing on UK real-world data, gives the likelihood of staying on treatment for more than 1 year as 67–73% for etanercept, 74–76% for adalimumab, 84–86% for ustekinumab, and 85–90% for guselkumab. Of 8,710 biologic-treated people, 11.5% switched and 31.1% discontinued, and switchers had higher adjusted total health care costs than nonswitchers (mean difference $10,120).
- Access: inability to obtain adequate insurance coverage was among the top reasons for discontinuing biological agents. Insurance plans in the USA often require patients to try and fail other treatments first (step therapy), a process that “often delays access to medically necessary treatments”. Several labels limit the indicated population: cyclosporine to severe, recalcitrant plaque psoriasis after failure of at least one systemic therapy or when other systemic therapies are contraindicated or not tolerated, brodalumab to patients who have failed to respond or lost response to other systemic therapies and only through a REMS program, and adalimumab and infliximab to patients for whom other systemic therapies are medically less appropriate.
Summary: efficacy of oral agents relative to biologics, safety warnings, and monitoring
- Efficacy in network meta-analyses: in a network meta-analysis of 204 studies with 67,889 randomized participants, anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF-alpha biologics showed a higher proportion of participants reaching PASI 90 than non-targeted and targeted systemic agents. At class level, the PASI 90 RR for anti-IL17 treatment was 3.20 versus TYK-2 inhibitors, 4.01 versus non-targeted systemic treatments, and 5.82 versus phosphodiesterase-4 inhibitors. Deucravacitinib and risankizumab were more effective than apremilast, and ciclosporin and methotrexate were superior to apremilast for PASI 90. A second network meta-analysis, of 60 trials, estimated PASI 90 at 10 to 16 weeks from baseline at 12.1% for apremilast and 11.4% for dimethyl fumarate, against 17.9% for etanercept, 43.7% for adalimumab, 43.9% for ustekinumab, 70.8% for ixekizumab, and 71.6% for risankizumab-rzaa. A review states that deucravacitinib was superior to apremilast and inferior to risankizumab.
- Limits of the comparative evidence: the network meta-analysis evidence is limited to induction therapy (outcomes from 8 to 24 weeks after randomisation), its participants had a mean age of 44.4 years and a baseline PASI of 20.5, and its serious adverse event analyses rested on a very low number of events. The guideline group of the EuroGuiDerm-adapted German S3 guideline stated it was not able to sufficiently differentiate recommendation levels for individual agents on PASI 90 and serious adverse events alone.
- Conventional oral agents: methotrexate achieved PASI 75 in 35.5% of patients against 79.6% with adalimumab, and acitretin 50 mg/d achieved PASI 75 in 23% after 8 weeks. Cyclosporine, methotrexate, and acitretin are described as having “limited efficacy and/or are associated with serious side effects and major monitoring requirements”.
- Safety warnings: the labels of adalimumab, etanercept, infliximab, and certolizumab pegol state an increased risk of serious infections that may lead to hospitalization or death, and the adalimumab label reports lymphoma and other malignancies in children and adolescents treated with TNF blockers. The JYLAMVO (methotrexate) label reports serious adverse reactions including death, and hepatotoxicity risk that generally occurs after a cumulative dose of 1.5 g or more. Cyclosporine can cause hypertension and nephrotoxicity (cyclosporine nephropathy in 18/86 [21%] of biopsied psoriasis patients). Acitretin must not be used by females who are pregnant or intend to become pregnant during therapy or for at least 3 years after discontinuation. Suicidal ideation and behavior, including completed suicides, have occurred with brodalumab, and bimekizumab carries a warning for suicidal ideation and behavior; oral candidiasis occurred in 19.3% with bimekizumab and 3.0% with secukinumab. The AAD-NPF biologics guideline recommends avoiding IL-17 inhibitors in patients with a personal history of or active IBD. With apremilast, depression was reported in 1.3% vs. 0.4% with placebo and weight decrease of 5%-10% in 12% vs. 5%, and diarrhea and nausea each occurred in 17%. The deucravacitinib label warns of infections, CPK elevation and rhabdomyolysis, and triglyceride elevations, and a review describes deucravacitinib as the only JAK or TYK2 inhibitor indicated for psoriasis that “does not have a boxed warning”. Class 1 topical corticosteroids are limited to up to 4 weeks, and tachyphylaxis may occur with use beyond 12 weeks.
- Screening and monitoring: deucravacitinib requires evaluation for active and latent tuberculosis before treatment and periodic evaluation of serum triglycerides; for icotrokinra, tuberculosis evaluation is considered based on clinical judgement and live vaccines are avoided. The adalimumab label directs monitoring of all patients for active tuberculosis during treatment, even if the initial latent test is negative; cyclosporine requires frequent monitoring of serum creatinine; the EuroGuiDerm-adapted guideline group monitors methotrexate with transaminases; and periodic assessment of suicidal ideation is recommended with brodalumab. Apremilast has no requirement for laboratory monitoring.
Untreated and undertreated psoriasis and treatment dissatisfaction, 2003 to 2011
“From 2003 through 2011, patients who were untreated ranged from 36.6% to 49.2% of patients with mild psoriasis, 23.6% to 35.5% of patients with moderate psoriasis, and 9.4% to 29.7% of patients with severe psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 52.3% of patients with psoriasis and 45.5% of patients with psoriatic arthritis were dissatisfied with their treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Untreated, lapsed, and switched treatment among insured U.S. patients with moderate to severe psoriasis
“There were an estimated 1.7 million insured US patients with moderate to severe psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 1 million (59%) were not treated for their condition in the preceding year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, an estimated 807,000 patients had lapsed treatment, an additional 346,000 were receiving treatment, and 547,000 were defined as being treatment-naive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 81,000 of 346,000 patients had switched treatment in the preceding year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insurance coverage and step therapy as barriers to biologic treatment
“Although adverse effects and a lack of effectiveness were primary reasons for discontinuing biological agents, the inability to obtain adequate insurance coverage was among the top reasons for discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite their efficacy and safety, patients are often required by insurance plans in the USA or national formulary guidelines in other countries to try and fail other treatments first, which is a strategy called step therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This process often delays access to medically necessary treatments, with patients’ conditions potentially worsening each day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Injection burden and preference for oral administration
“For example, respondents were willing to accept a reduction in the percentage of patients who achieve clear or almost-clear skin after treatment from approximately 70% to 40% to avoid injections at home and use a topical treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Topical treatments were the most preferred option of administration followed by oral agents and intravenous infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Completed surveys from 178 patients and 43 dermatologists were included in the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence and persistence to biologics: meta-analysis
“Sixty-two records met the inclusion criteria, and a meta-analysis was conducted on fifty-five studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the proportion of adherent and persistent patients to biological therapy was 0.61 (95% confidence interval: 0.48–0.73) and 0.63 (0.57–0.68), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The highest proportions were found for ustekinumab, while the lowest ones were found for etanercept.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Biologic switch rates at 12 and 24 months and predictors of switching
“A total of 7997 patients were included, with overall treatment switch rates at 14.4% at 12 months and 26.0% at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prior targeted immune modulator use, age, and female gender were predictors of switching (adjusted hazard ratio; 1.23, 1.31, and 1.40, respectively; p ≤ 0.0005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy gap of oral agents relative to biologics: network meta-analysis
“Biologic treatments anti‐IL17, anti‐IL12/23, anti‐IL23, and anti‐tumour necrosis factor (TNF)‐alpha showed a higher proportion of participants reaching PASI 90 than the non‐targeted systemic agents and the targeted systemic agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis evidence limited to induction-phase outcomes and trial populations
“This update includes 26 new studies, taking the total number of included studies to 204, and randomised participants to 67,889 (67% men), mainly recruited from hospitals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This network meta‐analysis evidence is limited to induction therapy (outcomes measured from 8 to 24 weeks after randomisation), and is not sufficient for evaluating longer‐term outcomes in this chronic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, we found low numbers of studies for some of the interventions, and the young age (mean 44.4 years) and high level of disease severity (PASI 20.5 at baseline) may not be typical of people seen in daily clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, the SAEs analyses were based on a very low number of events with low‐certainty evidence for most comparisons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the results of the network comparisons for the outcome measures PASI 90 and SAE alone, the guideline group is not able to sufficiently differentiate the recommendation levels for the individual agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote